General
Researchers Develop Bioengineered Gum to Combat Oral HPV
A new bioengineered chewing gum containing hyacinth bean protein has shown a 93% reduction in oral HPV in laboratory tests.
According to a report by Khaosod Online on August 17, 2026, researchers led by Professor Henry Daniell at the University of Pennsylvania School of Dental Medicine have developed a bioengineered chewing gum designed to target viruses linked to oral cancer. The study focuses on the FRIL protein found in the hyacinth bean (lablab bean), which prevents viruses from entering cells by causing them to clump together.
Laboratory tests on saliva samples indicated that the gum reduced the presence of the Human Papillomavirus (HPV)—a common sexually transmitted infection—by 93%. Professor Daniell stated that the gum is capable of neutralizing at least five types of oral viruses and is intended to be used as a supplementary treatment alongside conventional methods like radiation and surgery.
For residents and travelers in Thailand, this development represents a potential future advancement in oral health maintenance. However, it is important to note that this research is currently in the experimental stage. The gum is not yet available for public purchase, and further clinical trials are required to confirm its safety, long-term efficacy, and regulatory approval for human use. Individuals concerned about oral health or HPV should continue to consult with qualified medical professionals regarding established screening and vaccination protocols.